Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 104 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Mar. 31, 2013
Consolidated Statements Of Operations      
Revenues         
Total         
Operating expenses:      
Amortization & depreciation 194 152 76,543
General and administrative 233,641 2,031,147 12,801,590
Total 233,835 2,031,299 12,878,133
Gain (loss) from operations (233,835) (2,031,299) (12,878,133)
Other income (expense):      
Loss on fair value adjustment - derivatives (95,613)    (543,750)
Gain on debt reversal 5,571    5,571
Gain on sale of fixed asset    (4,790) (4,790)
Interest expense (40,400) (35,212) (1,133,392)
Interest expense - beneficial conversion feature (77,103) (20,136) (259,167)
Total (207,545) (50,558) (1,925,948)
Income (loss) before provision for income taxes (441,380) (2,081,857) (14,804,081)
Provision for income tax         
Net income (loss) (441,380) (2,081,857) (14,804,081)
Less: Net (income) loss attributable to noncontrolling interest 2,905 3,246 91,362
Net income (loss) attributable to TransBiotec, Inc. $ (438,475) $ (2,078,611) $ (14,712,719)
Net income (loss) per share (TransBiotec, Inc.)      
(Basic and fully diluted) $ (0.01) $ (0.08)  
Weighted average number of common shares outstanding 31,164,488 25,496,925